Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Economic impact of potential drug-drug interactions in opioid analgesics.

Summers KH, Puenpatom RA, Rajan N, Ben-Joseph R, Ohsfeldt R.

J Med Econ. 2011;14(4):390-6. doi: 10.3111/13696998.2011.583302. Epub 2011 May 17.

PMID:
21574905
2.

Economic impact of potential drug-drug interactions among osteoarthritis patients taking opioids.

Pergolizzi JV Jr, Labhsetwar SA, Puenpatom RA, Ben-Joseph R, Ohsfeldt R, Summers KH.

Pain Pract. 2012 Jan;12(1):33-44. doi: 10.1111/j.1533-2500.2011.00498.x. Epub 2011 Sep 27.

PMID:
21951824
3.

Exposure to potential CYP450 pharmacokinetic drug-drug interactions among osteoarthritis patients: incremental risk of multiple prescriptions.

Pergolizzi JV Jr, Labhsetwar SA, Puenpatom RA, Joo S, Ben-Joseph R, Summers KH.

Pain Pract. 2011 Jul-Aug;11(4):325-36. doi: 10.1111/j.1533-2500.2010.00438.x. Epub 2010 Dec 28.

PMID:
21199317
4.

Prevalence of exposure to potential CYP450 pharmacokinetic drug-drug interactions among patients with chronic low back pain taking opioids.

Pergolizzi JV Jr, Labhsetwar SA, Puenpatom RA, Joo S, Ben-Joseph RH, Summers KH.

Pain Pract. 2011 May-Jun;11(3):230-9. doi: 10.1111/j.1533-2500.2010.00413.x. Epub 2010 Aug 27.

PMID:
20807350
5.

Economic impact of potential CYP450 pharmacokinetic drug-drug interactions among chronic low back pain patients taking opioids.

Pergolizzi JV Jr, Labhsetwar SA, Amy Puenpatom R, Ben-Joseph R, Ohsfeldt R, Summers KH.

Pain Pract. 2012 Jan;12(1):45-56. doi: 10.1111/j.1533-2500.2011.00503.x. Epub 2011 Sep 16.

PMID:
21923882
6.

The prevalence of opioid-related major potential drug-drug interactions and their impact on health care costs in chronic pain patients.

Pergolizzi JV Jr, Ma L, Foster DR, Overholser BR, Sowinski KM, Taylor R Jr, Summers KH.

J Manag Care Spec Pharm. 2014 May;20(5):467-76.

7.

Quantifying the impact of drug-drug interactions associated with opioids.

Pergolizzi JV.

Am J Manag Care. 2011 Sep;17 Suppl 11:S288-92.

8.

Opioid pharmacokinetic drug-drug interactions.

Overholser BR, Foster DR.

Am J Manag Care. 2011 Sep;17 Suppl 11:S276-87. Review.

9.

Costs of gastrointestinal events after outpatient opioid treatment for non-cancer pain.

Kwong WJ, Diels J, Kavanagh S.

Ann Pharmacother. 2010 Apr;44(4):630-40. doi: 10.1345/aph.1M520. Epub 2010 Mar 2.

PMID:
20197473
10.

Detection and prevention of drug-drug interactions in the hospitalized elderly: utility of new cytochrome p450-based software.

Zakrzewski-Jakubiak H, Doan J, Lamoureux P, Singh D, Turgeon J, Tannenbaum C.

Am J Geriatr Pharmacother. 2011 Dec;9(6):461-70. doi: 10.1016/j.amjopharm.2011.09.006. Epub 2011 Oct 22.

PMID:
22019006
11.
12.

How frequently are contraindicated or warned against combinations of drugs prescribed to patients receiving long-term opioid therapy for chronic pain?

Richarz U, Jacobs A, Spina E.

Pharmacoepidemiol Drug Saf. 2012 May;21(5):453-62. doi: 10.1002/pds.2250. Epub 2011 Nov 14.

PMID:
22081534
13.

Healthcare costs and nonadherence among chronic opioid users.

Leider HL, Dhaliwal J, Davis EJ, Kulakodlu M, Buikema AR.

Am J Manag Care. 2011 Jan;17(1):32-40.

14.

Patient characteristics and prescription fill patterns for allergic rhinitis medications, with a focus on montelukast, in a commercially insured population.

Bollinger ME, Diette GB, Chang CL, Stephenson JJ, Sajjan SG, Fan T, Allen-Ramey FC.

Clin Ther. 2010 Jun;32(6):1093-102. doi: 10.1016/j.clinthera.2010.06.003.

PMID:
20637964
15.

Clinical comorbidities, treatment patterns, and direct medical costs of patients with osteoarthritis in usual care: a retrospective claims database analysis.

Gore M, Tai KS, Sadosky A, Leslie D, Stacey BR.

J Med Econ. 2011;14(4):497-507. doi: 10.3111/13696998.2011.594347. Epub 2011 Jun 20.

PMID:
21682606
16.

Financial and clinical characteristics of fibromyalgia: a case-control comparison.

Palacio A, Uribe CL, Li H, Hanna J, Deminski M, Alvir J, Chandran A, Sanchez R.

Am J Manag Care. 2010 May;16(5 Suppl):S118-25.

17.

Patterns of healthcare utilization and cost in patients with newly diagnosed fibromyalgia.

Berger A, Sadosky A, Dukes EM, Edelsberg J, Zlateva G, Oster G.

Am J Manag Care. 2010 May;16(5 Suppl):S126-37.

18.
19.

Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.

Pelletier EM, Ogale S, Yu E, Brunetta P, Garg J.

Clin Ther. 2009 Nov;31(11):2653-64. doi: 10.1016/j.clinthera.2009.11.032.

PMID:
20110008
20.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124

Supplemental Content

Support Center